RecruitingNot ApplicableNCT06911697
Study on c-Met Targeted PET/CT Imaging in NSCLC
In Vivo Detection of c-Met Activation Status by Specific PET/CT Imaging Based on 18F Labeled Small Molecule TKI
Sponsor
Xilin Sun
Enrollment
88 participants
Start Date
Oct 26, 2023
Study Type
INTERVENTIONAL
Conditions
Summary
The investigators developed a 18F labeled small molecule, 18F-TSPF, based on c-Met TKI, as a targeted molecular imaging agent for noninvasive and repeatable detecting c-Met activation status.
Eligibility
Min Age: 18 YearsMax Age: 75 Years
Inclusion Criteria8
- Age range 18-75 years, open to both male and female participants;
- Normal hepatic/renal function and cardiac function;
- Expected survival of at least 12 weeks;
- Good adherence to follow-up;
- Presence of at least one measurable target lesion according to RECIST 1.1 criteria;
- Women of childbearing age (15-49 years) must undergo a pregnancy test within seven days prior to the commencement of the study and test negative; sexually active male and female participants must agree to utilize effective contraception to prevent pregnancy during the study and for three months following the final examination;
- Patients for whom a clinical physician recommends PET/CT scans for the diagnosis and staging of tumors;
- Participants must fully understand and voluntarily agree to participate in the study, and must sign an informed consent form.
Exclusion Criteria7
- Severe abnormalities in liver and renal function and blood counts;
- Patients planning to conceive;
- Pregnant or lactating women;
- Individuals unable to lie flat for thirty minutes;
- Individuals who refuse to participate in this clinical study;
- Individuals suffering from claustrophobia or other psychiatric disorders;
- Other situations deemed unsuitable for trial participation by the researchers.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DIAGNOSTIC_TEST18F-TSPF PET/CT
Each subject receives interval imaging of 18F-TSPF PET/CT and 18F-FDG PET/CT, and further follow-up.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06911697
Related Trials
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
NCT073973385 locations
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
NCT0558100441 locations
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
NCT06422143207 locations
A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC)
NCT056578739 locations
Imaging-based PRediction of Eligibility for ChemoImmunotherapy in reSEctable NSCLC, iPRECISE
NCT075591231 location